Next Article in Journal / Special Issue
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection
Previous Article in Journal / Special Issue
Antimicrobial Use, Human Gut Microbiota and Clostridium difficile Colonization and Infection
Article Menu

Export Article

Open AccessReview
Antibiotics 2015, 4(3), 254-266; doi:10.3390/antibiotics4030254

Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond

1
Centre for Digestive Diseases, 1/229 Great North Rd, Five Dock, NSW 2046 Australia
2
Pleiades Advisors, 13 Oak Meadow Road, Lincoln, MA 01773, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Yung-Fu Chang
Received: 6 May 2015 / Revised: 25 June 2015 / Accepted: 26 June 2015 / Published: 6 July 2015
(This article belongs to the Special Issue Clostridium difficile Infection)
View Full-Text   |   Download PDF [604 KB, uploaded 6 July 2015]   |  

Abstract

Fecal Microbiota Transplantation (FMT) methodology has been progressively refined over the past several years. The procedure has an extensive track record of success curing Clostridium difficile infection (CDI) with remarkably few adverse effects. It achieves similar levels of success whether the CDI occurs in the young or elderly, previously normal or profoundly ill patients, or those with CDI in Inflammatory Bowel Disease (IBD). While using FMT to treat CDI, however, we learned that using the procedure in other gastrointestinal (GI) diseases, such as IBD without CDI, generally fails to effect cure. To improve results in treating other non-CDI diseases, innovatively designed Randomized Controlled Trials (RCTs) will be required to address questions about mechanisms operating within particular diseases. Availability of orally deliverable FMT products, such as capsules containing lyophilised fecal microbiota, will simplify CDI treatment and open the door to convenient, prolonged FMT delivery to the GI tract and will likely deliver improved results in both CDI and non-CDI diseases. View Full-Text
Keywords: Fecal microbiota transplantation; Clostridium difficile; inflammatory bowel disease; IBD; colitis; Crohn’s; irritable bowel Fecal microbiota transplantation; Clostridium difficile; inflammatory bowel disease; IBD; colitis; Crohn’s; irritable bowel
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Borody, T.J.; Peattie, D.; Mitchell, S.W. Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond. Antibiotics 2015, 4, 254-266.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top